Stuttgart - Delayed Quote EUR

BioXcel Therapeutics Inc. (US09075P1057.SG)

Compare

0.3289

+0.0003

+(0.09%)

At close: January 17 at 11:47:07 AM GMT+1

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 27 days ago

BTAI
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BioXcel Therapeutics Inc (BTAI) reports significant progress in pivotal trials and improved financial metrics despite revenue challenges.

GuruFocus.com 2 months ago

BTAI
Q3 2024 BioXcel Therapeutics Inc Earnings Call

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

BTAI
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

BTAI
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

BTAI
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BioXcel Therapeutics (BTAI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 4 months ago

BTAI
Q2 2024 BioXcel Therapeutics Inc Earnings Call

Q2 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

BTAI
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 72.37% and 38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

BTAI
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript May 9, 2024 BioXcel Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to the BioXcel Therapeutics First Quarter 2024 Earnings Conference Call. At this time, […]

Insider Monkey 8 months ago

BTAI
Q1 2024 BioXcel Therapeutics Inc Earnings Call

Q1 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 8 months ago

BTAI
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

BioXcel Therapeutics ( NASDAQ:BTAI ) Full Year 2023 Results Key Financial Results Net loss: US$179.1m (loss widened by...

Simply Wall St. 9 months ago

BTAI
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript March 12, 2024 BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]

Insider Monkey 10 months ago

BTAI
Q4 2023 BioXcel Therapeutics Inc Earnings Call

Q4 2023 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 10 months ago

BTAI
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy. It’s the reason why people collect everything from baseball cards to luxury Swiss watches. Stated differently, it doesn’t take much to explain the rationale behind short-squeeze stocks to buy. On the other hand, shorting a stock represents an incredibly complex affair by

InvestorPlace 10 months ago

NVAX

BTAI

BMEA
15 Hot Penny Stocks On the Move

In this article, we will take a detailed look at the 15 Hot Penny Stock On the Move. For a quick overview of such stocks, read our article 5 Hot Penny Stock On the Move. Strong inflation data from January and the Fed’s indications that it would take its time before initiating rate cuts threw cold […]

Insider Monkey 10 months ago

^GSPC

LXRX

RGTI

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioXcel Therapeutics Inc. (US09075P1057.SG)

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

Q3 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Q2 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

Q1 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

Q4 2023 BioXcel Therapeutics Inc Earnings Call

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

15 Hot Penny Stocks On the Move